Nasopharyngeal Cancer – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Nasopharyngeal Cancer – Pipeline Review, H1 2017’, provides an overview of the Nasopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer

– The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects

– The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advenchen Laboratories LLC

Ambrx Inc

arGEN-X BV

Ascentage Pharma Group Corp Ltd

Atara Biotherapeutics Inc

AVEO Pharmaceuticals Inc

BeiGene Ltd

Betta Pharmaceuticals Co Ltd

BioDiem Ltd

Biomics Biotechnologies Co Ltd

CBT Pharmaceuticals Inc

Celgene Corp

Cell Medica Ltd

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Neonc Technologies Inc

Novartis AG

Ono Pharmaceutical Co Ltd

Sapvax

Tessa Therapeutics Pte Ltd

Theravectys SA

Viracta Therapeutics Inc

Yabao Pharmaceutical Group Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Nasopharyngeal Cancer Overview 7

Nasopharyngeal Cancer Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Nasopharyngeal Cancer Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 19

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Nasopharyngeal Cancer Companies Involved in Therapeutics Development 26

Advenchen Laboratories LLC 26

Ambrx Inc 26

arGEN-X BV 27

Ascentage Pharma Group Corp Ltd 27

Atara Biotherapeutics Inc 28

AVEO Pharmaceuticals Inc 28

BeiGene Ltd 29

Betta Pharmaceuticals Co Ltd 29

BioDiem Ltd 30

Biomics Biotechnologies Co Ltd 30

CBT Pharmaceuticals Inc 31

Celgene Corp 31

Cell Medica Ltd 32

F. Hoffmann-La Roche Ltd 32

GlaxoSmithKline Plc 33

MedImmune LLC 33

Merck & Co Inc 34

Merck KGaA 34

Millennium Pharmaceuticals Inc 35

Neonc Technologies Inc 35

Novartis AG 36

Ono Pharmaceutical Co Ltd 36

Sapvax 37

Tessa Therapeutics Pte Ltd 37

Theravectys SA 38

Viracta Therapeutics Inc 38

Yabao Pharmaceutical Group Co Ltd 39

Nasopharyngeal Cancer Drug Profiles 40

alisertib Drug Profile 40

Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer Drug Profile 46

apatinib Drug Profile 47

APG-1387 Drug Profile 51

ARGX-110 Drug Profile 52

ATA-129 Drug Profile 57

atezolizumab Drug Profile 60

avelumab Drug Profile 77

azacitidine Drug Profile 86

baltaleucel-T Drug Profile 92

bevacizumab Drug Profile 94

BGBA-317 Drug Profile 106

CBT-501 Drug Profile 108

Cellular Immunotherapy for EBV Associated Malignancies Drug Profile 109

Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Cancer Drug Profile 110

Cellular Immunotherapy for Multiple Sclerosis and Nasopharyngeal Carcinoma Drug Profile 111

Cellular Immunotherapy for Nasopharyngeal Cancer Drug Profile 112

Cellular Immunotherapy for Oncology Drug Profile 113

Cellular Immunotherapy for Oncology Drug Profile 114

Cellular Immunotherapy for Oncology Drug Profile 116

Cellular Immunotherapy to Target EPCAM for Oncology Drug Profile 117

Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology Drug Profile 118

Cellular Immunotherapy to Target LMP1 for Epstein-Barr Virus Infections and Nasopharyngeal Cancer Drug Profile 119

DC-120 Drug Profile 120

donafenib Drug Profile 121

durvalumab + tremelimumab Drug Profile 122

EBViNT Drug Profile 127

Epstein-Barr virus vaccine Drug Profile 128

ficlatuzumab Drug Profile 129

GSK-2849330 Drug Profile 132

icotinib hydrochloride Drug Profile 133

JS-001 Drug Profile 135

MAK-683 Drug Profile 136

Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma Drug Profile 137

Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma Drug Profile 138

MVA vaccine Drug Profile 139

NEO-212 Drug Profile 140

nimotuzumab Drug Profile 141

nivolumab Drug Profile 145

PDR-001 Drug Profile 185

pembrolizumab Drug Profile 187

RO-5203280 Drug Profile 235

Small Molecule to Antagonize DDR1 Receptor for NSCLC and Nasopharyngeal Cancer Drug Profile 236

SV-638 Drug Profile 237

TT-10 Drug Profile 238

Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma Drug Profile 239

Vaccine for Oncology Drug Profile 240

Vaccine to Target EBV for Nasopharyngeal Carcinoma Drug Profile 241

Vaccine to Target LMP-2 for Nasopharyngeal Carcinoma Drug Profile 242

VRx-3996 Drug Profile 243

Nasopharyngeal Cancer Dormant Projects 245

Nasopharyngeal Cancer Discontinued Products 246

Nasopharyngeal Cancer Product Development Milestones 247

Featured News & Press Releases 247

Appendix 253

Methodology 253

Coverage 253

Secondary Research 253

Primary Research 253

Expert Panel Validation 253

Contact Us 253

Disclaimer 254

List of Tables

List of Tables

Number of Products under Development for Nasopharyngeal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Nasopharyngeal Cancer Pipeline by Advenchen Laboratories LLC, H1 2017

Nasopharyngeal Cancer Pipeline by Ambrx Inc, H1 2017

Nasopharyngeal Cancer Pipeline by arGEN-X BV, H1 2017

Nasopharyngeal Cancer Pipeline by Ascentage Pharma Group Corp Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by Atara Biotherapeutics Inc, H1 2017

Nasopharyngeal Cancer Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Nasopharyngeal Cancer Pipeline by BeiGene Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by BioDiem Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by Biomics Biotechnologies Co Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by CBT Pharmaceuticals Inc, H1 2017

Nasopharyngeal Cancer Pipeline by Celgene Corp, H1 2017

Nasopharyngeal Cancer Pipeline by Cell Medica Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by GlaxoSmithKline Plc, H1 2017

Nasopharyngeal Cancer Pipeline by MedImmune LLC, H1 2017

Nasopharyngeal Cancer Pipeline by Merck & Co Inc, H1 2017

Nasopharyngeal Cancer Pipeline by Merck KGaA, H1 2017

Nasopharyngeal Cancer Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Nasopharyngeal Cancer Pipeline by Neonc Technologies Inc, H1 2017

Nasopharyngeal Cancer Pipeline by Novartis AG, H1 2017

Nasopharyngeal Cancer Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by Sapvax, H1 2017

Nasopharyngeal Cancer Pipeline by Tessa Therapeutics Pte Ltd, H1 2017

Nasopharyngeal Cancer Pipeline by Theravectys SA, H1 2017

Nasopharyngeal Cancer Pipeline by Viracta Therapeutics Inc, H1 2017

Nasopharyngeal Cancer Pipeline by Yabao Pharmaceutical Group Co Ltd, H1 2017

Nasopharyngeal Cancer Dormant Projects, H1 2017

Nasopharyngeal Cancer Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Nasopharyngeal Cancer, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports